Sponsored For
Beginners Choice

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Malin Corporation plc is a biotechnology business based in Ireland. Malin shares (MLC) are listed on the IR and all prices are listed in Euros. Malin employs 250 staff and has a trailing 12-month revenue of around EUR€37.4 million.
Since the stock market crash in March caused by coronavirus, Malin's share price has had significant negative movement.
Its last market close was EUR€4.2, which is 0.47% down on its pre-crash value of EUR€4.22 and 200.00% up on the lowest point reached during the March crash when the shares fell as low as EUR€1.4.
If you had bought EUR€1,000 worth of Malin shares at the start of February 2020, those shares would have been worth EUR€379.15 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth EUR€995.27.
Latest market close | EUR€4.2 |
---|---|
52-week range | EUR€1.4 - EUR€5 |
50-day moving average | EUR€4.1326 |
200-day moving average | EUR€4.0745 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | EUR€-0.434 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the last close of €4.2
1 week (2021-01-11) | -4.55% |
---|---|
1 month (2020-12-18) | 5.53% |
3 months (2020-10-19) | -8.70% |
6 months (2020-07-17) | -12.13% |
1 year (2020-01-17) | -8.70% |
---|---|
2 years (2019-01-18) | -22.22% |
3 years (2018-01-18) | -51.72% |
5 years (2016-01-18) | -64.41% |
Revenue TTM | EUR€37.4 million |
---|---|
Gross profit TTM | EUR€7.5 million |
Return on assets TTM | -2.29% |
Return on equity TTM | -5.97% |
Profit margin | -30.21% |
Book value | €3.831 |
Market capitalisation | EUR€211.7 million |
TTM: trailing 12 months
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Takeda Pharmaceutical shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing Heat Biologics shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.